Sirolimus is also known as
rapamycin. Manufacturer
Wyeth uses the trade name
Rapamune. It is used to prevent rejection in kidney transplants.
Sirolimus is an immunosuppressant that can block T cell activation, as cyclosporine also does. There was a trial in 2003 called
Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia that studied the addition of sirolimus to the ATG and cyclosporine given to AA patients. That part of the study was stopped in 2005 due to lack of efficacy.
A trial called
Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia is currently recruiting participants. It is studying the safety and efficacy of combining sirolimus with cyclosporine. Perhaps this is the trial your doctor told you about, ccartbmw.
There are also trials testing sirolimus for prevention of Graft Versus Host Disease (GVHD) after stem cell transplants, so it may be useful to bone marrow failure patients in a number of ways.